secwatch.observer — SEC 8-K summary
======================================

Issuer:     KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
CIK:        0001877184
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-315896
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kestra Q2 FY26 revenue $22.6M (+53% YoY); guides FY26 to $91M (+52% YoY)
------------------------------------------------------------------------

- Gross margin expanded to 50.6% from 39.6% YoY, driven by volume leverage and a higher mix of in-network patients.
- GAAP net loss $32.8M; adjusted EBITDA loss $19.7M vs $16.1M prior year.
- Prescriptions for ASSURE system grew 54% YoY to 4,696; revenue benefited from market share gains and WCD market expansion.
- Raised FY26 revenue guidance to $91M (52% growth); cash $175M at Oct 31 (excl. $148M net from subsequent equity offering).
- CEO cites strong commercial momentum, positive post-approval study data, and balance sheet fortification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1877184/000119312525315896/0001193125-25-315896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1877184/000119312525315896/ck0001877184-20251211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-315896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer